113541-07-4

Basic information

• Product Name: Ethanone, 1,2-bis(2,4-dichlorophenyl)-2-hydroxy-
• CAS NO: 113541-07-4
• Molecular Formula: C14H8Cl4O2
• Molecular Weight: 350.028
• Mol File: 113541-07-4.mol

Chemical Properties

• CAS DataBase Reference: Ethanone, 1,2-bis(2,4-dichlorophenyl)-2-hydroxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1,2-bis(2,4-dichlorophenyl)-2-hydroxy-(113541-07-4)
• EPA Substance Registry System: Ethanone, 1,2-bis(2,4-dichlorophenyl)-2-hydroxy-(113541-07-4)

Safety Data

• Hazardous Substances Data: 113541-07-4(Hazardous Substances Data)

Upstream product

• 874-42-0 2,4-dichlorobenzaldeyhde 
• 104-88-1 4-chlorobenzaldehyde 
• 77287-34-4 formamide 

Downstream Products

• 489447-40-7 (+/-)-4'-chloro-2-hydroxy-2-(2,4-dichlorophenyl)acetophenone 
• 1615691-60-5 (4S,5S)-5-(2,4-dichlorobenzoyl)-5-(2,4-dichlorophenyl)-4-phenyldihydrofuran-2(3H)-one 
• 1372399-27-3 2,3-di(2,4-dichlorophenyl)quinoxaline 
• 489447-35-0 4,5-di-(2,4-dichlorophenyl)oxazole 
• 94171-15-0 2-(2,4-dichlorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)-2',4'-dichloropropiophenone 
• 94147-83-8 2-(2,4-dichlorobenzoyl)-2-(2,4-dichlorophenyl)oxirane 
• 107680-38-6 Toluene-4-sulfonic acid 2,3-bis-(2,4-dichloro-phenyl)-2-hydroxy-3-oxo-propyl ester 
• 107659-73-4 (4S,5R)-4,5-Bis-(2,4-dichloro-phenyl)-4-[1,2,4]triazol-1-ylmethyl-[1,3]dioxolan-2-one 
• 107659-45-0 (1R,2S)-1,2-Bis-(2,4-dichloro-phenyl)-3-[1,2,4]triazol-1-yl-propane-1,2-diol 
• 94146-95-9 1,2-Bis-(2,4-dichloro-phenyl)-2-hydroxy-3-[1,2,4]triazol-4-yl-propan-1-one 
• 94171-12-7 1,2-Bis-(2,4-dichloro-phenyl)-2-hydroxy-3-imidazol-1-yl-propan-1-one 
• 94146-88-0 (1S,2R)-1,2-Bis-(4-chloro-phenyl)-3-imidazol-1-yl-propane-1,2-diol 
• 107680-37-5 1,2-Bis-(2,4-dichloro-phenyl)-2,3-dihydroxy-propan-1-one 

Relevant articles and documents

Synthesis of functionalized γ-lactones via a three-component cascade reaction catalyzed by consecutive N-heterocyclic carbene systems

Two consecutive N-heterocyclic carbene (NHC) catalytic systems were combined in a one-pot cascade reaction for the assembly of aromatic aldehydes and 2-haloenals into a structurally complex γ-lactone backbone. To our knowledge, this is the first report of NHC-catalyzed [3 + 2] annulation of α,β-unsaturated acylazoliums with 1,2-bisnucleophiles.

One-pot asymmetric synthesis of substituted tetrahydrofurans via a multicatalytic benzoin/Michael/acetalization cascade

A sequential benzoin/Michael/acetalization tandem reaction catalyzed by NHC and amine together has been developed to assemble aromatic aldehydes and enals into chiral tetrahydrofuran derivatives bearing multiple functional groups and stereogenic centers with high stereoselectivity of up to 95:5 dr and 96% ee. The high yield and stereocontrol of this process may be due to both acid-promoted symmetrization of racemic acyloins and iminium ion activation of enals.

Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists

Structure-activity relationship studies directed toward the optimization of 4,5-diarylimidazole-2-carboxamide analogs as human CB1 receptor inverse agonists resulted in the discovery of the two amide derivatives 24a and b (hCB1 IC50 = 6.1 and 4

Substituted imidazoles as cannabinoid receptor modulators

The use of compounds of the present invention as antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor particularly in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor. The invention is concerned with the use of these novel compounds to selectively antagonize the Cannabinoid-1 (CB1) receptor. As such, compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith. Novel compounds of structural formula (I) are also claimed.